

Pathway for Accessing Treatments for Non-Hospitalised Adults and Children with Mild COVID-19 (Effective 26th June 2023)

Supporting Information available via [TeamNet](#)

Patient Registered^{i,ii} with a General Practice in Herefordshire and Worcestershire Presents to NHS Service Provider (Trust, GP, NHS111)

All NHS Service Providers Responsible for Confirming:

1. Positive COVID-19 Lateral Flow (registered via gov.uk or 119) or PCRⁱⁱⁱ Test
2. Symptomatic (onset within last 5 days) with COVID-19 and showing no signs of clinical recovery
3. Identified as Highest Risk (see [Independent Advisory Group Report](#))
4. COVID Management Delivery Unit (CMDU) have not already assessed patient (documented in EMIS; OneH record for Herefordshire and Community Access tab for Worcestershire)

AND
AND
AND

**Not
Eligible**

Hospital Referral if Indicated

Consider Eligibility for [PANORAMIC study](#):

- Age 50+ OR 18-49 with listed pre-existing condition AND
- COVID-19 symptoms beginning in the last 5 days AND
- Positive lateral flow or PCR test within past 7 days

1. Encourage patient to [self-enrol](#)
2. Provide [Participant Information](#)

Potentially^v Eligible^{vi}

REFER to CMDU ASAP or within 7 days of Positive test:

- [Staywell](#) (Worcestershire)
- [Taurus](#) (Herefordshire)
- Enter "COVID-19 Treatment Assessment" in title

Notes:

- For GPs: [C1649 letter](#) (published 31/05/2022) provides further guidance.
- For Trusts:
 - [C1645i letter](#) (published 08/06/2022) summarises changes in patient eligibility and actions for trust clinicians including new patient cohorts that need to be contacted.
 - [C1645ii](#) (published 08/06/22) summarises all patients within eligible cohorts who need to be contacted by consultants.
- For patients registered with a GP outside of Herefordshire and Worcestershire, refer to appropriate [CMDU service](#).

COVID Management Delivery Unit (CMDU)

1. Check referrals daily where possible; prioritise day 3-4 window
2. Remote triage to assess [eligibility](#) and suitability using "CMDU Assessment" EMIS template
3. Follow [NICE TA 878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19](#) to ensure appropriate treatment choice
4. Seek specialist advice where appropriate (see page 4/5)
5. Discuss < 18 years with responsible Specialist Paediatric Consultant/MDT where possible (see page 4/5)
6. Drug interactions via [University of Liverpool COVID-19 website](#)
7. Monitor eligible patients and provide [oximetry @home](#) where appropriate

Eligible^{vi} for COVID-19 Treatment
See page 2 overleaf

Notes:

- i. H&W residents testing positive Out of Area (OOA) should be assessed by H&W CMDU with [either FP10 for Paxlovid or sotrovimab](#) prescription issued to OOA [CMDU \(or equivalent\) service](#).
- ii. OOA patients testing positive in H&W should be assessed by their resident service who should [arrange an FP10 for Paxlovid](#) or send a [sotrovimab](#) prescription to the appropriate H or W CMDU service.
- iii. Clinicians requesting PCR tests for patients potentially eligible for COVID-19 treatments should clearly annotate the request with "clinical priority group"
- iv. GP Practice teams/NHS111 are not expected to make the final decision of whether the treatment is right for a patient or prescribe any treatment, rather to refer patients that meet the policy criteria in broad terms.
- v. The final decision about eligibility rests with the CMDU prescriber.
- vi. The pathway is based on available information and clinical opinion. It will be reviewed and updated, if required, as services develop, and national policy is updated.

Eligible for COVID-19 Treatments: Treatment Choice and CMDU Responsibilities

Ensure comprehensive assessment of clinical appropriateness to guide treatment choice with reference to:
[NICE TA 878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19](#)

Note: Please refer to the electronic versions at all times.

	1 st Line	2 nd Line
	PAXLOVID (SmPC) - Age 18 years & over	SOTROVIMAB (SmPC) - Age 12 years & over
Clinical Check Requirements	<ol style="list-style-type: none"> Confirm exclusions including: <ul style="list-style-type: none"> Pregnancy Severe hepatic or renal impairment¹ Assessing for Paxlovid treatment Interactions with COVID-19 antiviral therapies Liverpool Drug Interactions Checker Commence treatment within 5 days of symptom onset Counsel, specifically regarding: <ul style="list-style-type: none"> Pregnancy and contraception Gastro-intestinal side effects Completion of course, missed dose Issue PIL (Paxlovid); UKHSA leaflet; National patient website 	<ol style="list-style-type: none"> Paxlovid is contra-indicated or unsuitable Confirm exclusions including: <ul style="list-style-type: none"> Adolescents (aged 12 -17) weighing less than 40kg Use in pregnancy: where expected benefit to mother justifies the risk to the foetus; liaise with appropriate specialist Treatment is delivered within 5 days of symptom onset Counsel Issue PIL (Sotrovimab); National patient website
Actions	<ol style="list-style-type: none"> CMDUs to contact local services for pharmacy/specialist advice as needed (see page 4 and 5 overleaf). Prescribe treatment as appropriate: Paxlovid: Via NHS Community Pharmacies <ol style="list-style-type: none"> Discuss with patient: <ol style="list-style-type: none"> Preferred community pharmacy considering urgency of prescription. Standard prescription charges are applicable. Contacting the pharmacy to confirm when the prescription is ready. Arranging collection by an asymptomatic patient representative. Telephone the identified community pharmacy to: <ol style="list-style-type: none"> Confirm ability to fulfil prescription before sending via EPS. Confirm clinical checks have been completed. Community Pharmacists are also responsible for a clinical check and may request additional information. If requested, supply (via secure nhs.net email) the completed Checklist, see page 3 for further details regarding contacting community pharmacies and arrangements for urgent supply. Advise on patient plans for medication collection. Complete electronic FP10 and send to selected community pharmacy: <ol style="list-style-type: none"> Temporary EPS nomination may be necessary or an EPS token provided Include statement that it is a 'CMDU Service Prescription' and CMDU telephone number for queries in FP10 'pharmacy info' section. Activity Reporting to ICB <ol style="list-style-type: none"> Where a decision to prescribe is reversed, please ensure that both the provider and community pharmacy, as appropriate, are notified. Combination treatment with an nMAB and an antiviral is NOT routinely recommended Patients who have previously received treatment with an nMAB or antiviral, & who meet the eligibility criteria, may receive treatment for a subsequent episode, if clinically appropriate. Where supply availability is impacting choice of treatment, consider MDT discussion to agree optimum treatment for the patients' circumstances. 	Sotrovimab: Via Trust Pharmacy Departments <ol style="list-style-type: none"> Complete and sign internal EMIS prescription form: <ol style="list-style-type: none"> Available as an EMIS medication specific template. Note: Sotrovimab is not available via FP10 prescription. Send to Trust Pharmacy Department via secure nhs.net email as overleaf (with prescribing clinician EMIS consultation notes (to evidence clinician prescribed medication) and medication record)
Notes	<ol style="list-style-type: none"> Where a decision to prescribe is reversed, please ensure that both the provider and community pharmacy, as appropriate, are notified. Combination treatment with an nMAB and an antiviral is NOT routinely recommended Patients who have previously received treatment with an nMAB or antiviral, & who meet the eligibility criteria, may receive treatment for a subsequent episode, if clinically appropriate. Where supply availability is impacting choice of treatment, consider MDT discussion to agree optimum treatment for the patients' circumstances. 	

¹ See [SmPC](#) for dosing modification for moderate renal impairment.

Eligible for COVID-19 Treatments: Treatment Provision & Pharmacist Responsibilities

	PAXLOVID (SmPC) - Age 18 years & over		SOTROVIMAB (SmPC) - Age 12 years & over
Treatment Provision	<p>Herefordshire and Worcestershire</p> <p>Via patient's preferred community pharmacy (NHS Find a Pharmacy Service):</p> <ul style="list-style-type: none"> All pharmacies potentially will have stock or be able to obtain stock and dispense. This link provides details of usual opening hours including weekend and bank holidays. <p>Where concern regarding urgent treatment initiation (e.g. Days 4 and 5 of symptom onset) consider the Community Pharmacy Urgent Access Medicines Service:</p> <ul style="list-style-type: none"> These 35 pharmacies are requested to keep 2 packs of Paxlovid in stock. CMDU staff have been supplied with direct contact details of pharmacies. 		<p>Herefordshire</p> <p>WVT Pharmacy</p> <p>Worcestershire</p> <p>18yrs & over: Community IV team AND whcnhs.pharmacyhub@nhs.net</p> <p>Age <18 yrs: WAHT On-call Paediatrician via switchboard bleep 678 AND worcesterdispensary.pharmacy@nhs.net</p>
	<p>Responsibilities and Actions</p> <ol style="list-style-type: none"> Draw down prescription from the spine. Confirm: <ol style="list-style-type: none"> prescription has been generated by CMDU clinical check has been completed by prescriber there are no outstanding concerns to preclude use of Paxlovid Pharmacy Clinical Check and Dispensing Pharmacists are responsible for a clinical check. Additional clinical information including the completed Checklist may be requested from CMDUs, who will supply via secure nhs.net email. Provision of Paxlovid Patient Information Leaflet (PIL) and additional UKHSA Paxlovid leaflet, if not provided by CMDU. Counsel patient in line with Paxlovid PIL, specifically regarding: <ol style="list-style-type: none"> Pregnancy and contraception Gastro-intestinal side effects Completion of course, and missed dose Collect standard prescription charge if applicable. 		<ol style="list-style-type: none"> Service delivery arrangements (including patient transport if necessary) Medication supply IV administration Provider discharge letter to primary care with SNOMED code <p>Notes:</p> <ul style="list-style-type: none"> Where all attempts at IV access fail despite optimising conditions, discuss with CMDU clinician. If paediatric service limitations, escalate to Medical Director/COO/bed manager for individual case discussion Discussion of individual circumstances may be required where capacity concerns. Prioritise patients by symptom duration. No prescription charge associated with sotrovimab use.

Resource Signposting

- In addition to resources on pages 1 and 2 of this document a complete list of resources are available via [Liverpool COVID-19 Interactions \(covid19-druginteractions.org\)](https://www.liverpool-lsc.nhs.uk/covid19-druginteractions.org) including:
 - [Guidance for resuming paused or dose-adjusted comedications with Paxlovid](#)
 - [Swallowing Difficulties - Administering Paxlovid as Crushed Tablets](#)
 - [Guidance for Paxlovid dosing in patients with renal disease and patients on dialysis](#)
 - [COVID-19 Therapies – Dose Recommendations for Patients with Renal Impairment](#)
 - [COVID-19 Therapies - Dose Recommendations for Patients with Hepatic Impairment](#)
- Specialist Pharmacy Service Medicines Advice contact details: telephone 0300 770 8564 or email asksp@nhs.uk
- E-Learning training materials: COVID-19 Treatments is available [here](#) (Registration on NHS Learning Hub is required)
- [PAXLOVID \(nirmatrelvir/ritonavir\) - PfizerPro UK](#)
- Specialist Pharmacy Service: Accessing COVID-19 Medicines Advice for Primary Care: Oral Antivirals Programme Poster (link to be added once available)
- [COVID-19 Antivirals – Community Pharmacy Herefordshire and Worcestershire](#)